Tafenoquine paediatric

GSK

Legend
Product category

  • Tafenoquine paediatric dispersible tablet
Product vision

  • Anti-relapse therapy for P. vivax malaria-infected children
Dosing

  • Single-dose treatment in children who cannot take the adult tablet 

  • Final dose regimen/weight banding to be confirmed based on paediatric study final analysis
Efficacy
  • Under investigation (unapproved)
Key features

  • Single-dose treatment to prevent relapse of P. vivax malaria

  • Contraindicated in G6PD deficiency
Challenges

  • Quantitative testing for G6PD deficiency required

  • Clarity around continued role for primaquine (G6PD-deficient patients)
Status
  • Paediatric pharmacokinetics bridging study currently ongoing 
Next milestone

  • Paediatric pharmacokinetics bridging study readout
MMV Project Director

  • Dr Isabelle Borghini